Printer Friendly

RHONE-POULENC RORER SUB-LICENSES PENETREX(R) ANTIBIOTIC FROM WARNER-LAMBERT AND DAINIPPON FOR NORTH AMERICAN MARKET

 RHONE-POULENC RORER SUB-LICENSES PENETREX(R) ANTIBIOTIC FROM
 WARNER-LAMBERT AND DAINIPPON FOR NORTH AMERICAN MARKET
 COLLEGEVILLE, Pa., July 16 /PRNewswire/ -- Rhone-Poulenc Rorer Inc. (NYSE: RPR) announced today it has signed a sub-licensing agreement with Warner-Lambert Company (NYSE: WLA) and Dainippon Pharmaceuticals Company, Ltd. for a new fluoroquinolone antibiotic, Penetrex(R) (enoxacin).
 Under the terms of the agreement, RPR will assume responsibility for all manufacturing and marketing of Penetrex in the North American market, including the United States, Canada and Puerto Rico. Warner-Lambert will receive a royalty based on sales volume.
 Warner-Lambert originally licensed the product from Dainippon, managed the development process and obtained FDA approval for the NDA in December 1991.
 Penetrex is indicated for the treatment of complicated and uncomplicated urinary tract infection (UTI) and uncomplicated urethral or cervical gonorrhea. The brand will be promoted by the specialty division at RPR. Its advantages include excellent tissue penetration and a high clinical success rate in treating UTI. It is administered on a twice-daily regimen.
 "Penetrex is the foundation on which we will build our anti-infective franchise in the U.S.," said Randy H. Thurman, executive vice president, RPR, and president, RPR Pharmaceuticals Inc. "It is a valuable niche product for us that provides a good strategic fit with our current product portfolio, and will help to establish RPR's presence in the anti-infective market. We are also very pleased to build on our strong partnerships with Dainippon and with Warner-Lambert."
 RPR is currently involved in a joint venture with Dainippon in Europe for the development of sparfloxacin, a new, advanced broad spectrum quinolone antibiotic which has the potential to become a first- line therapy with once-daily dosing for respiratory tract infections in adults. In March 1992, RPR announced a co- development, co-marketing agreement with Warner-Lambert for sparfloxacin in North America. Sparfloxacin is currently in phase III of development.
 Rhone-Poulenc Rorer is a global pharmaceutical company dedicated to the discovery, development, manufacturing and marketing of human pharmaceuticals. The company reported sales of $3.8 billion in 1991 and will invest $500 million in research and development in 1992.
 /delval/
 -0- 7/16/92
 /CONTACT: Rhone-Poulenc Rorer media relations, 215-454-3871, or investor relations, 215-454-3851/
 (RPR) CO: Rhone-Poulenc Rorer Inc. ST: Pennsylvania IN: MTC SU: LIC


LJ -- PH007 -- 9892 07/16/92 09:15 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 16, 1992
Words:380
Previous Article:INAMED CORPORATION TO BUY BACK SHARES
Next Article:NYNEX REPORTS SECOND QUARTER 1992 RESULTS; NET INCOME UP 14 PERCENT FROM A YEAR AGO
Topics:


Related Articles
WARNER-LAMBERT, RHONE-POULENC RORER AGREE TO CO-DEVELOP AND CO-PROMOTE ADVANCED QUINOLONE ANTIBACTERIAL IN U.S. AND CANADA
WARNER-LAMBERT, RHONE-POULENC RORER AGREE TO CO-DEVELOP AND CO-PROMOTE ADVANCED QUINOLONE ANTIBACTERIAL IN U.S. AND CANADA
RHONE-POULENC RORER REPORTS CONTINUED STRONG GROWTH IN EARNINGS: ACHIEVING ADDITIONAL EFFICIENCIES AND CREATING STRATEGIC PARTNERSHIPS
LABORATOIRE BELLON ANNOUNCES PRODUCT RECALL OF JOSACINE
RHONE-POULENC RORER MAKES INVESTIGATIONAL ANTIBIOTIC AVAILABLE VIA EMERGENCY USE PROGRAM
RHONE-POULENC RORER FILES NEW DRUG APPLICATION FOR SPARFLOXACIN, AN ANTIBIOTIC TO TREAT COMMUNITY-ACQUIRED RESPIRATORY TRACT INFECTIONS
/C O R R E C T I O N -- Rhone-Poulenc Rorer/(Correction Notice)
ALERT: Respiratory Illness Hits U.S. Earlier and Harder This Year
German In Vitro Studies Reveal Increasing Prevalence and Spread Of Serious Infection-Causing Pathogens
Does quinupristin/dalfopristin (Synercid[R]) treat nosocomial pneumonia comparably to vancomycin?

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters